Immune cell therapy for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new approach using your own immune cells (tumor-infiltrating lymphocytes) that have been modified to work better, followed by a combination of oral chemo and immunotherapy. It's for people with ovarian cancer that has come back after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 80 years old.
- You have recurrent epithelial ovarian cancer that has grown after at least one prior treatment.
- You are in good enough health to undergo surgery to remove a tumor, with a performance status of 0 or 1 (able to carry out daily activities).
- Your cancer can be measured on scans, and you have at least one lesion that can be removed surgically.
- You have adequate organ function (heart, lungs, kidneys, liver, and blood counts) and a negative test for certain infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This trial tests a new type of immune therapy called CAR T-cells (SCT-001) for ovarian cancer that has returned or isn't responding to standard treatments. The cells are engineered to find and attack cancer cells that have a specific marker (TAG-72) on their surface.
This trial tests whether a combination of two drugs, fluzoparil and apatinib, can help keep ovarian cancer from coming back after platinum chemotherapy. It is for people whose cancer has either returned within 6 months (platinum-resistant) or after 6 months (platinum-sensitive) and who have responded to at least 4 more cycles of chemotherapy.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.